Advertisement

Topics

Charles River Laboratories and Chiesi Farmaceutici SpA Announce Extension of Integrated Respiratory Drug Discovery Program

08:00 EDT 13 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), today announced that it has extended its longstanding, strategic, integrated drug discovery partnership with...

Other Sources for this Article

Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
amy.cianciaruso@crl.com

NEXT ARTICLE

More From BioPortfolio on "Charles River Laboratories and Chiesi Farmaceutici SpA Announce Extension of Integrated Respiratory Drug Discovery Program"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...